GSK Pays $90M To Settle States' Claims Over Avandia Risks
GlaxoSmithKline PLC has agreed to pay $90 million to settle the claims of 37 states and the District of Columbia that it had unlawfully misrepresented the cardiovascular-related risks of diabetes treatment...To view the full article, register now.
Already a subscriber? Click here to view full article